Does circulating BNP normalize after heart transplantation in patients with normal hemodynamic and right and left heart functions?

Clinical Transplantation

Volumn 22, Issue 5, 2008, Pages 542-548

  Talha, Samy ^a   Di Marco, P ^a   Doutreleau, S ^a   Rouyer, O ^a   Piquard, F ^a   Geny, B ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Brain natriuretic peptide; Diastolic function; Echocardiography; Emodynamics; Endothelin; Right ventricular function; Transplantation

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; CORTICOSTEROID; CYCLIC GMP; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; BODY MASS; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION FUNCTION; DOPPLER ECHOGRAPHY; ECHOCARDIOGRAPHY; HEART FAILURE; HEART HEMODYNAMICS; HEART TRANSPLANTATION; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYCLIC GMP; ECHOCARDIOGRAPHY, DOPPLER; ENDOTHELIN-1; HEART FAILURE; HEART TRANSPLANTATION; HEMODYNAMICS; HUMANS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT;

EID: 52649124788     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00818.x     Document Type: Article

References (42)

1. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998: 135: 825.
2. Luchner A, Burnett JC Jr., Jougasaki M et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000: 18: 1121.
3. Tulevski II, Groenink M, van Der Wall EE et al. Increased brain and atrial natriuretic peptide in patients with chronic right ventricular pressure overload: Correlation between plasma neurohormones and right ventricular dysfunction. Heart 2001: 86: 27.
4. Charloux A, Piquard F, Doutreleau S, Brandenberger G, Geny B. Mechanisms of renal hyporesponsiveness to atrial natriuretic peptide in heart failure. Eur J Clin Invest 2003: 33: 769.
5. Geny B, Piquard F, Lonsdorfer J, Haberey P. Endothelin and heart transplantation. Cardiovasc Res 1998: 39: 556.
6. Doutreleau S, Piquard F, Lonsdorfer E et al. Improving exercise capacity, 6weeks training tends to reduce circulating endothelin after heart transplantation. Clin Transplant 2004: 18: 672.
7. Geny B, Brandenberger G, Lonsdorfer J, Chakfe N, Haberey P, Piquard F. Circulating adrenomedullin is increased after heart-transplantation. Cardiovasc Res 1999: 41: 731.
8. Geny B, Follenius M, Epailly E et al. Transient reduction without normalization of brain natriuretic peptide early after heart transplantation. J Thorac Cardiovasc Surg 1998: 115: 473.
9. Masters RG, Davies RA, Veinot JP, Hendry PJ, Smith SJ, de Bold AJ. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 1999: 20: 287.
10. Park MH, Uber PA, Scott RL, Mehra MR. B-type natriuretic peptide in heart transplantation: An important marker of allograft performance. Heart Fail Rev 2003: 8: 359.
11. Ogawa T, Veinot JP, Davies RA et al. Neuroendocrine profiling of humans receiving cardiac allografts. J Heart Lung Transplant 2005: 24: 1046.
12. Mehra MR, Uber PA, Potluri S, Ventura HO, Scott RL, Park MH. Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. Am J Cardiol 2004: 15: 454.
13. Geny B, Ellero B, Chakfe N, Kretz JG, Brandenberger G, Piquard F. Cardiac diastolic dysfunction in renal-transplant recipients is associated with increased circulating adrenomedullin. Clin Transplant 2006: 20: 330.
14. Arnau-Vives MA, Almenar L, Hervas I et al. Predictive value of brain natriuretic peptide in the diagnosis of heart transplant rejection. J Heart Lung Transplant 2004: 23: 850.
15. Hervas I, Arnau MA, Almenar L et al. Ventricular natriuretic peptide (BNP) in heart transplantation: BNP correlation with endomyocardial biopsy, laboratory and hemodynamic measures. Lab Invest 2004: 84: 138.
16. Park MH, Scott RL, Uber PA, Harris BC, Chambers R, Mehra MR. Usefulness of B-type natriuretic peptide levels in predicting hemodynamic perturbations after heart transplantation despite preserved left ventricular systolic function. Am J Cardiol 2002: 90: 1326.
17. Geny B, Charloux A, Lampert E, Lonsdorfer J, Haberey P, Piquard F. Enhanced brain natriuretic peptide response to peak exercise in heart-transplant recipient. J Appl Physiol 1998: 85: 2270.
18. El Gamel A, Yonan NA, Keevil B et al. Significance of raised natriuretic peptides after bicaval and standard cardiac transplantation. Ann Thorac Surg 1997: 63: F1095.
19. Sundereswaran L, Nagueh SF, Vardan S et al. Estimation of left and right ventricular filling pressures after heart transplantation by tissue Doppler imaging. Am J Cardiol 1998: 82: 352.
20. Ationu A, Burch M, Singer D, Littleton P, Carter N. Cardiac transplantation affects ventricular expression of brain natriuretic peptide. Cardiovasc Res 1993: 27: 188.
21. Geny B, Saini J, Mettauer B et al. Effect of short term endurance training on exercise capacity, hemodynamics and atrial natriuretic peptide secretion in heart transplant recipients. Eur J Appl Physiol 1996: 73: 259.
22. Geny B, Richard R, Mettauer B, Lonsdorfer J, Piquard F. Cardiac natriuretic peptides during exercise and training after heart transplantation. Cardiovasc Res 2001: 51: 521.
23. Geny B, Piquard F, Follenius M et al. Role of cardiac innervation on atrial natriuretic peptide secretion in transplanted heart recipients. Am J Physiol 1993: 265: F112.
24. Geny B, Piquard F, Follenius M et al. Atrial natriuretic factor secretion: A role for atrial systolic ejection force? Eur J Appl Physiol 1996: 72: 440.
25. Schaefer A, Piquard F, Doutreleau S et al. Reduced exercise capacity is associated with reduced nitric oxide production after heart transplantation. J Thorac Cardiovasc Surg 2001: 122: 821.
26. Kubo SH, Rector TS, Bank AJ et al. Effects of cardiac transplantation on endothelium-dependent dilation of the peripheral vasculature in congestive heart failure. Am J Cardiol 1993: 71: 88.
27. Geny B, Piquard F, Follenius M et al. Endothelin participates in increased circulating atrial natriuretic peptide early after human heart transplantation. J Heart Lung Transplant 1998: 17: 167.
28. Piquard F, Doutreleau S, Richard R et al. Is increased circulating endothelin associated with increased complication rate after heart transplantation? J Heart Lung Transpl 2002: 21: 719.
29. O'Neill JO, Mc Rae AT III, Troughton RW et al. Brain natriuretic peptide levels do not correlate with acute cellular rejection in de novo orthotopic heart transplant recipients. J Heart Lung Transplant 2005: 24: 416.
30. Mehra MR, Uber PA, Walther D et al. Gene expression profiles and B-type natriuretic peptide elevation in heart transplantation: More than a hemodynamic marker. Circulation 2006: 4:(Suppl. 1): I21.
31. Mehra MR, Uber PA, Vivekananthan K et al. Comparative beneficial effects of simvastatin and paravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 2002: 40: 1609.
32. Ma KK, Ogawa T, De Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 2004: 36: 505.
33. Shaw SM, Fildes J, Yonan N, Williams SG. Does brain natriuretic peptide interact with the immune system after cardiac transplantation? Transplantation 2007: 84: 1377.
34. Piquard F, Geny B, Ellero B et al. Role of immunosuppressive therapy in neuroendocrine activation after human heart, renal and liver transplantation. Transplant Proc 1998: 30: 2124.
35. Tie-Min W, Lie J, Ling-Chun L, Bao-Jin Z, Le-Xin W. Changes in plasma B-type natriuretic peptide after allograft renal transplantation. Nephrology 2007: 12: 102.
36. Horl WH. Natriuretic peptides in acute and chronic kidney disease and during renal replacement therapy. J Invest Med 2005: 53: 366.
37. Therapondos G, Flapan AD, Dollinger MM, Garden OJ, Plevris JN, Hayes PC. Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: A prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus. Liver Transpl 2002: 8: 690.
38. Shalev A, Nir A, Granot E. Cardiac function in children post-orthotopic liver transplantation: Echocardiographic parameters and biochemical markers of subclinical cardiovascular damage. Pediatr Transplant 2005: 9: 718.
39. Geny B, Hardy H, Lonsdorfer J, Eisenmann B, Haberey P, Piquard F. Enhanced natriuretic response to neutral endopeptidase inhibition in heart-transplant recipients. Hypertension 1999: 33: 969.
40. Feldman DS, Ikonomidis JS, Uber WE et al. Human B-natriuretic peptide improves hemodynamics and renal function in heart transplant patients immediately after surgery. J Card Fail 2004: 10: 292.
41. Klingenberg R, Koch A, Gleissner C et al. Determinants of B-type natriuretic peptide plasma levels in the chronic phase after heart transplantation. Transpl Int 2005: 18: 169.
42. D'Souza SP, Yellon DM, Martin C et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 2003: 284: 1592.